Tags : Neovascular Age-Related Macular Degeneration

Genentech Reports Results of Port Delivery System with Ranibizumab in

Shots: The P-III Archway study involves assessing of PDS with ranibizumab, refilled @6mos. at fixed intervals, vs ranibizumab (0.5mg, monthly IVT) in 418 patients with nAMD, prior treated with VEGF therapy Results: 98.4% of PDS patients were able to go 6mos. without needing additional treatment and achieved vision outcomes equivalent to patients receiving ranibizumab (0.5mg, […]Read More

Roche Reports Results of Port Delivery System with Ranibizumab in

Shots: The P-III Archway study involves assessing the efficacy and safety of Port Delivery System with ranibizumab (PDS), refilled q6w at fixed intervals vs monthly IVT of ranibizumab (0.5mg) in 418 people with nAMD The P-III Archway study resulted in meeting its 1EP i.e. patients achieved visual acuity outcomes equivalent and is well tolerated with […]Read More

Allergan Reports the Acceptance of EMA’s MAA for Abicipar to

Shots: Molecular Partners announces that EMA has validated the MAA of its partner Allergan for Abicipar to treat patients with nAMD Post-approval, Abicipar will be the first anti-VEGF therapy to maintain vision gains with a 12-week dosing interval. The companies collaborated to advance clinical programs in ophthalmology and to robust pipeline of DARPin drug candidates […]Read More